Bioibérica Farma, the only Spanish company specializing in the treatment of osteoarthritis, launches an osteoarthritis awareness campaign. According to the World Health Organization (WHO), osteoarthritis is the fourth most common cause of loss of Quality Adjusted Life Years.
Dr. Cristóbal Orellana, Associate Physician at the Service of Rheumatology of the Parc Taulí Hospital (Sabadell, Barcelona) commented that biomarkers extracted from type II collagen, a type of collagen that can be found only in the cartilage, holds great promise for diagnosing osteoarthritis, and for monitoring its treatment.
The delegation, which brought together experts from different Mexican states, visited Bioibericas headquarters in Catalonia on September 15, 2011
Genetics, key to predict the progression of osteoarthritis
The 19th edition of the symposium on glyccosaminoglyccans New developments of anticoagulant and non-anticoagulant glycosaminoglycans and of other coagulation inhibitors, is the most important meeting dealing with glycosaminoglycans. It will be held on 22-24 September 2011 at Villa Vigoni (Loveno, Lake Como)